Methadone Ap-Hp (Methadone Hydrochloride)

Methadone works by binding as a full agonist to the μ‑opioid receptors in the brain and spinal cord. This activation mimics natural endorphins, producing analgesia and suppressing the neural pathways that cause opioid withdrawal, while its long half‑life allows stable plasma concentrations.

The dose of methadone is individualized and determined by the prescribing clinician based on the patient’s opioid tolerance, clinical condition, and response to therapy. Dosing may be adjusted during treatment to achieve optimal control of pain or withdrawal symptoms.

Data on methadone use in pregnancy and lactation are limited. It may be prescribed when the benefits to the mother outweigh potential risks to the fetus or infant. Healthcare providers should discuss potential effects and monitor both mother and child closely.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methadone and buprenorphine are the primary opioid agonist therapies for dependence. Methadone is a full μ‑opioid receptor agonist with a longer half‑life, allowing once‑daily dosing, while buprenorphine is a partial agonist with a ceiling effect on respiratory depression, which may offer a different safety profile.

Store Methadone Ap-Hp at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from moisture, direct sunlight, and accidental ingestion. Keep the product out of reach of children and handle according to standard pharmacy safety procedures.

Methadone Ap-Hp is administered orally. The tablet (or oral formulation) should be swallowed whole with a full glass of water. Doses are taken as prescribed, typically once daily for maintenance therapy, but the exact schedule is determined by the treating clinician.

The most serious risks include respiratory depression, especially during dose initiation or when combined with other CNS depressants, and cardiac arrhythmias due to QT‑interval prolongation. Patients should be educated to seek immediate medical attention if they experience shallow breathing, severe dizziness, or palpitations.

Methadone should be avoided in individuals with known hypersensitivity to methadone, uncontrolled severe respiratory disease, significant cardiac conduction abnormalities (e.g., prolonged QT interval), or those taking contraindicated medications that could cause dangerous interactions. A thorough medical assessment is required before initiation.